(Sharecast News) - Polymetal International: Berenberg upgrades to buy with a target price of 1,480p.
easyJet: UBS reiterates sell with a target price of 1,240p.
GVC Holdings: Peel Hunt reiterates buy with a target price of 1,050p.
Hikma Pharmaceuticals: Peel Hunt reiterates hold with a target price of 2,050p.
Spirent Communications: Liberum Capital reiterates buy with a target price of 238p.
Whitbread: Deutsche Bank upgrades to hold with a target price of 4,550p.
Playtech: Deutsche Bank upgrades to buy with a target price of 471p.
William Hill: Deutsche Bank downgrades to hold with a target price of 205p.
Avast: Barclays reiterates overweight with a target price of 510p.
Computacenter: Barclays reiterates equalweight with a target price of 1,550p.
Sage Group: Barclays reiterates underweight with a target price of 620p.
Joules Group: Peel Hunt reiterates buy with a target price of 250p.
SIG: Liberum Capital downgrades to hold with a target price of 100p.
Mitchells & Butlers: Barclays reiterates underweight with a target price of 405p.
Marks & Spencer: Barclays reiterates overweight with a target price of 250p.
EnQuest: JP Morgan upgrades to overweight with a target price of 40p.
Cairn Energy: JP Morgan reiterates overweight with a target price of 264p.
Spectris: Morgan Stanley downgrades to underweight with a target price of 2,500p.
Consort Medical: RBC Capital Markets downgrades to underperform with a target price of 1,010p.
Diploma: RBC Capital Markets downgrades to underperform with a target price of 1,500p.
Ferguson: RBC Capital Markets downgrades to underperform with a target price of 5,900p.
ASOS: Shore Capital Markets upgrades to hold with a target price of 3,489p.
Convatec: UBS upgrades to buy with a target price of 235p.
Dunelm: UBS downgrades to neutral with a target price of 310p.
18 Nov 2019 10:50
ShoreCap downgrades Consort Medical to 'hold' after all-cash offer from Recipharm
(Sharecast News) - Analysts at ShoreCap downgraded their recommendation for shares of Consort Medical from 'buy' to 'hold' following the recommended cash offer from Recipharm.
Read more
